Strontium guidance unchanged

NICE has again reissued its advice on the use of strontium ranelate (Protelos).

There is no change to the agency’s 2008 recommendation that the drug should be prescribed on the NHS for primary and secondary prevention of osteoporotic fractures only in patients at high risk of osteoporotic fractures who are unable to tolerate oral bisphosphonates.

NICE was obliged to re-examine its original judgment in 2010 after failing to disclose the underlying economic assumptions. The latest reassessment marks final confirmation of the guidance.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more